TAK Stock Recent News

Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q2 2023 Earnings Conference Call October 26, 2023 6:00 AM ET Company Participants Christopher O'Reilly - Head of Investor Relations Christophe Weber - President and Chief Executive Officer Andy Plump - President of R&D Costa Saroukos - Chief Financial Officer Julie Kim - President, U.S. Business Unit and U.S. Country Head Ramona Sequeira - President, Global Portfolio Division Conference Call Participants Hidemaru Yamaguchi - Citigroup Shinichiro Muraoka - Morgan Stanley Seiji Wakao - J.P. Morgan Steve Barker - Jefferies Kazuaki Hashiguchi - Daiwa Securities Michael Nedelcovych - TD Cowen Miki Sogi - Bernstein Akinori Ueda - Goldman Sachs Christopher O'Reilly Thank you very much for joining us out of your busy schedule today for the earnings call for Second Quarter Fiscal 2023 with Takeda Pharmaceutical Company Limited.

Japan's biggest drugmaker Takeda Pharmaceutical on Thursday slashed its full-year profit forecast by 36% as it contends with disappointments in its development pipeline and the loss of patent protection on key products.

High yields may seem attractive, however, homework can go a long way. Takeda's Phase 3 ADMIRE CD II study & Phase 3 EXCLAIM-2 trial both failed to meet key endpoints, thus impacting the company's FY23 outlook. When the company reports Q2 earnings on October 26, don't be surprised if FY23 forecasts are revised downward.

Takeda 4502, -0.33% said Tuesday its trial of darvadstrocel in the treatment of complex Crohn's Perianal Fistulas didn't meet its primary endpoint based on topline data.

American depositary receipts of Takeda Pharmaceutical Co. 4502, -1.79% TAK, -2.16% rose more than 1% in the extended session Tuesday after the Japan-based company said its dengue vaccine got the recommendation from an immunizations advisory board with the World Health Organization. The WHO will consider the recommendation in the coming weeks, the company said.

Takeda Pharmaceutical said on Monday it would be working with the U.S. health regulator towards a voluntary withdrawal of its lung cancer therapy in the country, after it failed to meet the main goal in a late-stage study.

Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States.

Shares of ImmunoGen Inc. IMGN, +1.45% jumped 1.7% in premarket trading Monday, after the Massachusetts-based drug maker announced a collaboration with Takeda Pharmaceutical Co. Ltd. TAK, +0.59% 4502, +0.52% to commercialize its Elahere ovarian cancer treatment in Japan.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

One of these high-yield pharma stocks stands out as a better buy right now.